LinKinVax is a clinical-stage biotech developing a protein-based vaccine platform that targets dendritic cells (CD40) via a humanized monoclonal antibody fused to regions of pathogens. The platform is adaptable to viral and bacterial pathogens and to mutations, and benefits from the safety profile of protein-based vaccines used for over 30 years. Three products are in or about to enter clinical trials: a prophylactic HIV vaccine currently in Phase I/IIa, a SARS-CoV-2 vaccine covering variants of interest, and a therapeutic vaccine for HPV-related cancers. The technology is predicated on work by the Vaccine Research Institute/Inserm with participation from UPEC and the Mondor Institute of Biomedical Research (IMRB). Financially, LinKinVax completed a new €7.3M financing initiated in 2022 and closed in December 2022, following seed funding from private shareholders earlier in 2022 and prior support from Bpifrance. The company intends to use the proceeds to accelerate its clinical development program and to position for a Series A of up to €50M. LinkinVax is a clinical-stage biotech developing an adaptable protein-based vaccine platform designed to respond to changes and mutations in target pathogens. The company leverages research conducted at the Vaccine Research Institute (VRI/INSERM/UPEC) to accelerate vaccine availability. Leadership includes André-Jacques Auberton-Hervé and Prof. Yves Lévy, MD, PhD. LinkinVax plans to use the new funds to accelerate the clinical development of its platform. In May 2021 Bpifrance granted LinkinVax €31m under a Covid-related PIA PSCP program and the French Government "Plan Relance." The company was founded in 2020 and is based in Paris, France.

Total raised

$13M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2023